Vertex Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Vertex Pharmaceuticals
VRTX Stock  USD 452.13  1.23  0.27%   
Vertex Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Vertex Pharmaceuticals' valuation are provided below:
Gross Profit
6.2 B
Profit Margin
0.3135
Market Capitalization
116.2 B
Enterprise Value Revenue
9.432
Revenue
11.7 B
We have found one hundred twenty available fundamental trend indicators for Vertex Pharmaceuticals, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Vertex Pharmaceuticals current market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 9.4 B in 2026. Enterprise Value is likely to drop to about 9.4 B in 2026

Vertex Pharmaceuticals Total Revenue

13.31 Billion

Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 13.3 B, Gross Profit of 11.5 B or Other Operating Expenses of 13.6 B, as well as many indicators such as Price To Sales Ratio of 10.28, Dividend Yield of 0.0 or PTB Ratio of 7.62. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Vertex Stock
Check out the analysis of Vertex Pharmaceuticals Correlation against competitors.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Vertex Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets27.2 B25.9 B10.3 B
Slightly volatile
Short and Long Term Debt Total2.1 B2 B923 M
Slightly volatile
Total Current Liabilities4.3 B4.1 B1.6 B
Slightly volatile
Total Stockholder Equity19.8 B18.9 B7.3 B
Slightly volatile
Property Plant And Equipment Net3.1 B3 B1.2 B
Slightly volatile
Cash5.5 B5.3 B3.6 B
Slightly volatile
Non Current Assets Total15.6 B14.9 B4.6 B
Slightly volatile
Non Currrent Assets Other1.2 B1.1 B327.5 M
Slightly volatile
Cash And Short Term Investments7.4 B7 B4.3 B
Slightly volatile
Common Stock Shares Outstanding157 M296.6 M230.2 M
Slightly volatile
Liabilities And Stockholders Equity27.2 B25.9 B10.3 B
Slightly volatile
Non Current Liabilities Total3.1 B2.9 B1.4 B
Slightly volatile
Other Current Assets803.8 M765.6 M336.3 M
Slightly volatile
Other Stockholder Equity8.1 B7.7 B6.3 B
Slightly volatile
Total Liabilities7.4 B7 B2.9 B
Slightly volatile
Total Current Assets11.6 B11 B5.7 B
Slightly volatile
Short Term Debt53.9 M106.1 M75.6 M
Very volatile
Accounts Payable498.7 M474.9 M183 M
Slightly volatile
Property Plant And Equipment Gross4.4 B4.2 B1.6 B
Slightly volatile
Net Receivables1.9 B1.9 B743.7 M
Slightly volatile
Common Stock Total Equity1.9 M3 M2.3 M
Slightly volatile
Common Stock2 M3 M2.3 M
Slightly volatile
Current Deferred Revenue249.7 M237.8 M152.7 M
Slightly volatile
Other Assets1.7 B1.6 B712.9 M
Slightly volatile
Long Term Debt446.2 M646.2 M555.2 M
Pretty Stable
Short Term Investments1.9 B1.8 B763.8 M
Slightly volatile
Property Plant Equipment1.8 B1.7 B923 M
Slightly volatile
Other Liabilities828.1 M788.7 M402.9 M
Slightly volatile
Inventory1.5 B1.4 B389 M
Slightly volatile
Good Will1.3 B1.3 B540.9 M
Slightly volatile
Intangible Assets997.3 M949.8 M473.2 M
Slightly volatile
Long Term Debt Total632.6 M619.9 M572.6 M
Very volatile
Capital Surpluse6.9 B8.5 B6.5 B
Slightly volatile
Deferred Long Term Liabilities6.9 M7.3 M87.7 M
Slightly volatile
Non Current Liabilities Other395.1 M233.7 M353.9 M
Slightly volatile
Capital Lease Obligations2.1 B2 B534.3 M
Slightly volatile
Short and Long Term Debt732.3 M697.4 M395.5 M
Slightly volatile
Long Term Investments6.2 B5.9 B1.2 B
Slightly volatile
Net Invested Capital10.9 B18.9 B7.2 B
Slightly volatile
Net Working Capital6.6 B6.9 B4.4 B
Slightly volatile
Capital Stock2.8 M3 M2.6 M
Slightly volatile

Vertex Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue13.3 B12.7 B5.1 B
Slightly volatile
Gross Profit11.5 B10.9 B4.4 B
Slightly volatile
Other Operating Expenses13.6 B12.9 B4.3 B
Slightly volatile
Total Operating Expenses11.7 B11.2 B3.6 B
Slightly volatile
Depreciation And Amortization248.5 M236.7 M106.3 M
Slightly volatile
Research Development4.4 B4.2 B1.9 B
Slightly volatile
Selling General Administrative1.8 B1.7 B731.5 M
Slightly volatile
Extraordinary Items1.9 B1.8 B1.5 B
Slightly volatile
Non Recurring102.7 M104 M121.6 M
Very volatile
Selling And Marketing Expenses24 M28.3 M33.6 M
Slightly volatile
Interest Income722.2 M687.8 M208 M
Slightly volatile
Reconciled Depreciation139.2 M238.3 M107.1 M
Slightly volatile

Vertex Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow12.5 B11.9 B4.1 B
Slightly volatile
Depreciation250.2 M238.3 M106.6 M
Slightly volatile
Capital Expenditures359.5 M342.4 M162.3 M
Slightly volatile
End Period Cash Flow5.5 B5.3 B3.6 B
Slightly volatile
Stock Based Compensation843.4 M803.3 M369.5 M
Slightly volatile
Change To Netincome437.4 M512.4 M412.4 M
Slightly volatile
Issuance Of Capital Stock347.9 M394.7 M318 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio10.2810.8215.294
Slightly volatile
PTB Ratio7.625.6911.8412
Slightly volatile
Days Sales Outstanding59.0561.351.6091
Slightly volatile
Book Value Per Share60.2257.3526.881
Slightly volatile
Stock Based Compensation To Revenue0.06920.07290.1003
Slightly volatile
Capex To Depreciation1.11.291.522
Very volatile
PB Ratio7.625.6911.8412
Slightly volatile
EV To Sales10.010.5314.9207
Slightly volatile
Inventory Turnover1.391.463.1995
Slightly volatile
Days Of Inventory On Hand272259175
Pretty Stable
Sales General And Administrative To Revenue0.260.210.2622
Slightly volatile
Research And Ddevelopement To Revenue0.360.380.619
Slightly volatile
Capex To Revenue0.02950.03110.0623
Slightly volatile
Cash Per Share22.4421.3816.3252
Slightly volatile
Intangibles To Total Assets0.140.09770.1213
Slightly volatile
Current Ratio2.943.13.5231
Very volatile
Tangible Book Value Per Share53.250.6623.2395
Slightly volatile
Receivables Turnover8.567.877.6901
Slightly volatile
Shareholders Equity Per Share60.2257.3526.6965
Slightly volatile
Debt To Equity0.120.10660.3435
Slightly volatile
Capex Per Share1.091.040.6152
Slightly volatile
Revenue Per Share40.4438.5218.8084
Slightly volatile
Interest Debt Per Share6.536.223.6552
Slightly volatile
Debt To Assets0.08480.08930.1666
Slightly volatile
Graham Number13913262.5869
Slightly volatile
Operating Cycle322307222
Slightly volatile
Price Book Value Ratio7.625.6911.8412
Slightly volatile
Company Equity Multiplier1.781.241.7983
Slightly volatile
Long Term Debt To Capitalization0.20.170.2145
Slightly volatile
Total Debt To Capitalization0.08240.08670.2208
Slightly volatile
Debt Equity Ratio0.120.10660.3435
Slightly volatile
Quick Ratio2.572.713.3555
Very volatile
Cash Ratio1.41.472.0678
Pretty Stable
Days Of Inventory Outstanding272259175
Pretty Stable
Days Of Sales Outstanding59.0561.351.6091
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.511.841.1041
Slightly volatile
Price To Book Ratio7.625.6911.8412
Slightly volatile
Fixed Asset Turnover2.43.843.9168
Pretty Stable
Debt Ratio0.08480.08930.1666
Slightly volatile
Price Sales Ratio10.2810.8215.294
Slightly volatile
Asset Turnover0.250.440.4767
Pretty Stable
Gross Profit Margin1.090.990.9378
Pretty Stable
Price Fair Value7.625.6911.8412
Slightly volatile

Vertex Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap9.4 B16.2 B17.4 B
Very volatile
Enterprise Value9.4 B15.8 B17.2 B
Very volatile

Vertex Fundamental Market Drivers

Forward Price Earnings23.753
Cash And Short Term Investments6.1 B

Vertex Upcoming Events

5th of February 2024
Upcoming Quarterly Report
View
6th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Vertex Pharmaceuticals Financial Statements

Vertex Pharmaceuticals investors use historical fundamental indicators, such as Vertex Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue237.8 M249.7 M
Total Revenue12.7 B13.3 B
Cost Of Revenue1.8 B1.8 B
Stock Based Compensation To Revenue 0.07  0.07 
Sales General And Administrative To Revenue 0.21  0.26 
Research And Ddevelopement To Revenue 0.38  0.36 
Capex To Revenue 0.03  0.03 
Revenue Per Share 38.52  40.44 
Ebit Per Revenue(0.02)(0.02)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
JBLJabil Circuit
MRKMerck Company
AMGNAmgen Inc

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY